On the contrary, pre-treatment of bona fide cancer-stem like cell line ANV2 with TGF-β1 resulted in delayed tumor growth, reduced tumorigenicity (100% in vehicle vs. 87% in TGF-β1 pre-treated group) and prolonged overall survival (Fig. S5E-F). The gene discussed is TGFB1; the disease is cancer.